Your browser doesn't support javascript.
loading
Management of Primary Tectal Plate Low-Grade Glioma in Pediatric Patients: Results of the Multicenter Treatment Study SIOP-LGG 2004.
Kaufmann, Ariane; Gerber, Nicolas U; Kandels, Daniela; Azizi, Amedeo A; Schmidt, Rene; Warmuth-Metz, Monika; Pietsch, Torsten; Kortmann, Rolf-Dieter; Gnekow, Astrid K; Grotzer, Michael A.
Afiliação
  • Kaufmann A; Department of Oncology, University Children's Hospital, Zurich, Switzerland.
  • Gerber NU; Department of Oncology, University Children's Hospital, Zurich, Switzerland.
  • Kandels D; Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Bayern, Germany.
  • Azizi AA; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Schmidt R; Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
  • Warmuth-Metz M; Department of Neuroradiology, University of Wuerzburg, Wuerzburg, Germany.
  • Pietsch T; Institute of Neuropathology, University of Bonn, Bonn, Germany.
  • Kortmann RD; Department of Radiation Oncology, University of Leipzig, Leipzig, Germany.
  • Gnekow AK; Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Bayern, Germany.
  • Grotzer MA; Department of Oncology, University Children's Hospital, Zurich, Switzerland.
Neuropediatrics ; 49(5): 314-323, 2018 10.
Article em En | MEDLINE | ID: mdl-29890518
ABSTRACT

BACKGROUND:

Tectal plate low-grade gliomas (LGGs) most often present with increased intracranial pressure and sometimes as incidental findings from brain imaging. Prognostic factors predicting outcome are largely unknown.

METHODS:

From 2004 until 2012, 71 patients with tectal plate LGG from Germany and Switzerland were followed within the SIOP-LGG 2004 study. Median age at diagnosis was 9.7 (range 0.1-17.5) years, and median follow-up time of surviving patients was 6.3 (interquartile range 4.9-8.3) years.

RESULTS:

A total of 41 out of 71 patients received no tumor treatment (12 with and 29 without biopsy). The 10-year event-free survival (EFS) rate (± standard error ) for patients with an initial tumor volume of ≤3 cm3 was 56% (±7%), as opposed to 12% (±8%) for those with tumors >3 cm3 (p < 0.001). The 10-year EFS for patients without contrast enhancement on initial magnetic resonance imaging (MRI) was 52% (±9%), and for those with enhancement, it was 23% (±9%) (p = 0.003). The 10-year overall survival rate was 96% (±3%) (death due to disease, 1; ventriculoperitoneal shunt infection, 1). Sixty-three (89%) patients had at least one cerebrospinal fluid diversion procedure.

CONCLUSIONS:

More than half of patients were managed without tumor treatment. Favorable prognostic factors for EFS were small initial tumor volume (≤3cm3) and the absence of initial contrast enhancement on MRI. Overall survival was excellent.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Teto do Mesencéfalo / Avaliação de Resultados em Cuidados de Saúde / Glioma Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neuropediatrics Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Teto do Mesencéfalo / Avaliação de Resultados em Cuidados de Saúde / Glioma Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Neuropediatrics Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça